EUVIMED · CrossrefZeitschrift
Clinical Genitourinary Cancer
ISSN 1558-7673 · Elsevier BV
Neueste Artikel
Functional Outcomes of High-Risk Prostate Cancer Patients Treated With Neoadjuvant Androgen Deprivation Therapy (nADT) Prior to Radical Prostatectomy
Time to Partial Nephrectomy Versus Cancer-Specific Mortality in 2 to 4 cm Renal Cell Carcinoma
Long-Term Outcomes of Focal Irreversible Electroporation for Localized Prostate Cancer: Results of a Prospective Pilot Study With Extended Follow-up
Efficacy and Safety of Second-Line Cabozantinib After IO-IO Versus IO-TKI Combination Therapy and the Impact of Reduced Starting Dose in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study
Real-World Determinants of Therapeutic Choice in Metastatic Renal Cell Carcinoma: A Machine Learning Analysis of Practice Patterns from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Pre-existing Metabolic Syndrome and Cardiometabolic Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Cohort Study Using the TriNetX Network
Safety and Efficacy of Immune Checkpoint Inhibitors Plus Bacillus Calmette–Guérin for High-Risk Non–Muscle-Invasive Bladder Cancer: A Bayesian Re-analysis of a Published Frequentist Meta-analysis
Cardiovascular Adverse Event Reporting Signals Associated with Concomitant Use of Androgen Receptor Pathway Inhibitors (ARPIs) And Cardiovascular Treatments
Comparison of Three Maintenance Protocols for First-line Intravesical Gemcitabine in Asian Patients with Non-muscle-invasive Bladder Cancer: A Multicenter, Retrospective Cohort Study
Baseline Cardiovascular Risk, Body Composition Changes, and Survival Outcomes During Intensified Androgen Deprivation Therapy in Locally Advanced and Metastatic Hormone Sensitive Prostate Cancer
Longitudinal somatic mutational dynamics in ctDNA from patients with metastatic castration-resistant prostate cancer receiving androgen receptor–directed therapy
Treatment Patterns and Survival Outcomes in Urachal Carcinoma: A Multicenter Real-World Study of 50 Patients from the West Japan Uro-oncology Collaboration Group
Clinical characteristics and treatment patterns in cisplatin-eligible versus cisplatin-ineligible muscle-invasive bladder cancer patients with intent for resection: A multi-country retrospective chart review in Europe
Risk Factors and Treatment Outcomes in Metastatic Prostate Cancer With Brain Metastases
Sex-Specific Differences in Disease-Free, Progression-Free and Overall Survival Following Enfortumab Vedotin Therapy for Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis
Quality-of-Life in CRPC Patients Treated With Enzalutamide Versus Abiraterone: Impact of Standard and Modified Dosing
Association Between Enfortumab Vedotin-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis
Treatment Type and Mortality for Black Versus White Patients With Muscle-Invasive Bladder Cancer
The Contemporary Pattern of Radical Cystectomy in the Treatment of High-Grade Non-Muscle Invasive Bladder Cancer
Pre-therapeutic PSMA PET Imaging Biomarkers Demonstrate Prognostic Value in Patients Undergoing [177Lu]Lu-PSMA Therapy: A Systematic Review and Meta-analysis
PARP Inhibitor Plus Androgen-receptor Signaling Inhibitor Versus the Same Inhibitor Alone in Homologous-Recombination-Repair-Altered Metastatic Prostate Cancer Across the Hormone-Sensitive and Castration-Resistant Continuum: A Systematic Review and Meta-Analysis
GLP-1RAs Use and Postoperative Outcomes in T2DM Patients Undergoing Radical Nephrectomy
Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response
Age at Diagnosis and Postoperative Outcomes Among Men Treated for Prostate Cancer in the U.S. Military Health System
Prognostic Value of Double-expressor Phenotype and an Exploratory DEP-IPI Risk Model in Primary Testicular Diffuse Large B-cell Lymphoma: A Multicenter Retrospective Cohort Study
Nomograms for Predicting Recurrence and Oncologic Outcomes After Partial Nephrectomy for Renal Cell Carcinoma
Evaluating Circulating DNA as a Prognostic Biomarker in Bladder Cancer Subtypes: A Preliminary Short Report
Prognostic Impact of Initial Management Strategies in Metachronous Oligometastatic Renal Cell Carcinoma: A Real-World Evidence
Immunophenotyping and Molecular Patterns of Prostate Cancer in East Africa: Diagnostic and Prognostic Implications—A Systematic Review
Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy
EUVIMED